Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.
10.3904/kjim.2008.23.3.156
- Author:
Su Jin MOON
1
;
Hee Jeoung YOON
;
Sung Ho HER
;
Jong Min LEE
;
Ho Jung AN
;
Yune Jeong LEE
;
Seung Won JIN
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. miinee@paran.com
- Publication Type:Case Report
- Keywords:
Abciximab;
Pericarditis
- MeSH:
Aged;
Angioplasty, Transluminal, Percutaneous Coronary/*adverse effects;
Antibodies, Monoclonal/*adverse effects;
Anticoagulants/*adverse effects;
Cardiac Tamponade/*etiology/therapy;
Emergency Medical Services;
Hemorrhage/*etiology/therapy;
Humans;
Immunoglobulin Fab Fragments/*adverse effects;
Korea;
Male;
Pericardiocentesis;
Pericarditis/*etiology/therapy;
Platelet Aggregation Inhibitors/*adverse effects;
Risk Factors
- From:The Korean Journal of Internal Medicine
2008;23(3):156-160
- CountryRepublic of Korea
- Language:English
-
Abstract:
Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
